Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 8/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.42 |
| ▸ | MTOR | P42345 | 5/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321371 | 0.86 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DMTOR | |
| SCHEMBL6395827 | 0.75 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL9937466 | 0.75 | PDK1 (0.35) | MTORPIK3R1PIK3CAIRAK4 | |
| SCHEMBL10707012 | 0.74 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4974288 | 0.74 | FPR2 (0.37) | MTORPIK3R1PIK3CAIRAK4 | |
| SCHEMBL4974284 | 0.74 | FPR2 (0.37) | MTORPIK3R1PIK3CAIRAK4 | |
| SCHEMBL10707551 | 0.74 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL9937328 | 0.71 | SMN1; SMN2 (0.37) | MTORPIK3R1PIK3CAIRAK4 | |
| SCHEMBL1719503 | 0.71 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL10706029 | 0.70 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877756-B2 | Substituted pteridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| EP-2032585-B1 | SUBSTITUTED PTERIDINES AS THERAPEUTIC AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-20100120766-A1 | Substituted Pteridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| US-7674788-B2 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120766-A1 | Substituted Pteridines | PMP22, TLR5, NQO1 | PDE4A 1376/4885PDE4B 1580/4885PDE4C 1418/4885 |
| US-20070287704-A1 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.